These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 24682036)
1. Evaluation of polycaprolactone matrices for the intravaginal delivery of metronidazole in the treatment of bacterial vaginosis. Pathak M; Turner M; Palmer C; Coombes AG J Biomater Appl; 2014 Sep; 29(3):354-63. PubMed ID: 24682036 [TBL] [Abstract][Full Text] [Related]
2. Sustained Simultaneous Delivery of Metronidazole and Doxycycline From Polycaprolactone Matrices Designed for Intravaginal Treatment of Pelvic Inflammatory Disease. Pathak M; Coombes AGA; Ryu B; Cabot PJ; Turner MS; Palmer C; Wang D; Steadman KJ J Pharm Sci; 2018 Mar; 107(3):863-869. PubMed ID: 29100864 [TBL] [Abstract][Full Text] [Related]
3. Controlled delivery of the antiprotozoal agent (tinidazole) from intravaginal polymer matrices for treatment of the sexually transmitted infection, trichomoniasis. Fernando HV; Chan LL; Dang N; Santhanes D; Banneheke H; Nalliah S; Coombes AGA Pharm Dev Technol; 2019 Mar; 24(3):348-356. PubMed ID: 29799300 [TBL] [Abstract][Full Text] [Related]
4. Investigation of Polycaprolactone Matrices for Intravaginal Delivery of Doxycycline. Pathak M; Coombes AGA; Turner MS; Palmer C; Wang D; Steadman KJ J Pharm Sci; 2015 Dec; 104(12):4217-4222. PubMed ID: 26398713 [TBL] [Abstract][Full Text] [Related]
5. An evaluation of polycaprolactone matrices for vaginal delivery of the antiviral, tenofovir, in preventing heterosexual transmission of HIV. Dang NT; Sivakumaran H; Harrich D; Coombes AG J Pharm Sci; 2013 Oct; 102(10):3725-35. PubMed ID: 23904196 [TBL] [Abstract][Full Text] [Related]
6. Development of intra-vaginal matrices from polycaprolactone for sustained release of antimicrobial agents. Dang NT; Turner MS; Coombes AG J Biomater Appl; 2013 Jul; 28(1):74-83. PubMed ID: 22684517 [TBL] [Abstract][Full Text] [Related]
7. Controlled release of metronidazole from composite poly-ε-caprolactone/alginate (PCL/alginate) rings for dental implants. Lan SF; Kehinde T; Zhang X; Khajotia S; Schmidtke DW; Starly B Dent Mater; 2013 Jun; 29(6):656-65. PubMed ID: 23602170 [TBL] [Abstract][Full Text] [Related]
8. The effects of intravaginal clindamycin and metronidazole therapy on vaginal lactobacilli in patients with bacterial vaginosis. Nyirjesy P; McIntosh MJ; Gattermeir DJ; Schumacher RJ; Steinmetz JI; Joffrion JL Am J Obstet Gynecol; 2006 May; 194(5):1277-82. PubMed ID: 16647910 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of microporous polycaprolactone matrices for controlled delivery of antiviral microbicides to the female genital tract. Asvadi NH; Dang NT; Davis-Poynter N; Coombes AG J Mater Sci Mater Med; 2013 Dec; 24(12):2719-27. PubMed ID: 23892484 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of polycaprolactone matrices for sustained vaginal delivery of nevirapine in the prevention of heterosexual HIV transmission. Dang N; Sivakumaran H; Harrich D; Shaw PN; Coombes AGA J Pharm Sci; 2014 Jul; 103(7):2107-2115. PubMed ID: 24867411 [TBL] [Abstract][Full Text] [Related]
11. Precipitation casting of drug-loaded microporous PCL matrices: incorporation of progesterone by co-dissolution. Chang HI; Williamson MR; Perrie Y; Coombes AG J Control Release; 2005 Sep; 106(3):263-72. PubMed ID: 15993508 [TBL] [Abstract][Full Text] [Related]
12. Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route. Dang NT; Sivakumaran H; Harrich D; Shaw PN; Davis-Poynter N; Coombes AG Eur J Pharm Biopharm; 2014 Oct; 88(2):406-14. PubMed ID: 24887313 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of bacterial vaginosis with high dosage metronidazole and lactic acid]. Andreeva P; Slavchev B; Kovachev S; Nacheva A; Vacheva R Akush Ginekol (Sofiia); 2002; 41(5):36-9. PubMed ID: 12440337 [TBL] [Abstract][Full Text] [Related]
14. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. Ferris DG; Litaker MS; Woodward L; Mathis D; Hendrich J J Fam Pract; 1995 Nov; 41(5):443-9. PubMed ID: 7595261 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis. Hillier SL; Lipinski C; Briselden AM; Eschenbach DA Obstet Gynecol; 1993 Jun; 81(6):963-7. PubMed ID: 8497364 [TBL] [Abstract][Full Text] [Related]
16. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Beigi RH; Austin MN; Meyn LA; Krohn MA; Hillier SL Am J Obstet Gynecol; 2004 Oct; 191(4):1124-9. PubMed ID: 15507930 [TBL] [Abstract][Full Text] [Related]
17. Metatranscriptome Analysis of the Vaginal Microbiota Reveals Potential Mechanisms for Protection against Metronidazole in Bacterial Vaginosis. Deng ZL; Gottschick C; Bhuju S; Masur C; Abels C; Wagner-Döbler I mSphere; 2018 Jun; 3(3):. PubMed ID: 29875146 [TBL] [Abstract][Full Text] [Related]